diabetestalk.net

Lidl Ireland To Offer Free Diabetes Screening To Customers And Staff At Several Locations Across The Country Over Next Three Months

Lidl Ireland to offer free diabetes screening to customers and staff at several locations across the country over next three months

Lidl Ireland to offer free diabetes screening to customers and staff at several locations across the country over next three months

LIDL Ireland will offer free diabetes screening for staff and customers at several of their shops across the country over the next three months.
The supermarket has teamed up with Diabetes Ireland for an intensive community screening programme aimed at raising awareness of the growing numbers being diagnosed with Prediabetes and Type 2 diabetes.
4
The screening service kicked off on Monday – and will be available at ten Irish locations for customers in the coming weeks.
And staff can avail of it at 92 stores, warehouses and offices across the country.
The number of people living with diabetes here is estimated to be 225,840 according to research from Diabetes Ireland.
As well as screenings being offered to the public, 5,000 Lidl staff who are part of their Health & Wellness programme will also be tested on the purpose built Lidl double decker bus travelling around Ireland.
Lidl employees can book their appointments online, and will involve a personal and family history questionnaire.
It will also involve a finger prick test, BMI measurements and waist circumference measurements with the analysis of the medical data provided immediately and confidentially to the employee.
Alamy 4
Meanwhile customer screenings are located in an adjacent area and will involve a diabetes risk assessment and screening.
No appointment is necessary and specialist Diabetes Ireland personnel will be on hand to offer advice and guidance on the condition.
Locations across all four provinces will be visited before the programme wraps up in September.
CHECK YOUR OLD STERLING
Rarest and most valuable ' Continue reading

Rate this article
Total 1 ratings
The Unicorn Frappuccino Diabetes Meme: An Appraisal

The Unicorn Frappuccino Diabetes Meme: An Appraisal


The Unicorn Frappuccino Diabetes Meme: An Appraisal
The best way to strengthen a meme is to wag your finger at it. Internet jokes metastasize when given attention, and it does not matter whether the attention is positive or negative, whether the voice is chuckling or chastising. Like a grease fire, the more one tries to douse a meme with splashes of disapproval, the hotter and faster it will burn. To indulge in another metaphor, any hint of admonishment becomes a drop of blood in the web-water, which attracts frenzied schools of troll-sharks. Anyone who has grown up with the Internet understands this on an intuitive level.
Having established the fact that you should never talk about a meme if you want it to go away, lets talk about a meme. You may have seen the meme in question: the Unicorn Frappucino Diabetes meme. Yes? No? You may also ask, quite fairly: why am I here, willingly bleeding into troll-infested waters?
A quick aside for those of you who dont know what Im talking about: An article or two recently called out Starbuckss Unicorn Frappuccino (new! limited time only!) for containing more than twice the acceptable amount of daily sugar intake [sic]. The import of this accusation is a little unclear, but google the Unicorn Frappuccino, and boy-howdy, things will begin to crystallize. 76 grams of sugar. 80 total carbs. Yikes.
Memesters quickly took this data and used it to fashion diabetes jokes, which were built on the premise that consuming lots of sugar causes diabetes (a specious and unscientific premise; well examine it in a moment).
Even some websites got Continue reading

Study: New oral drug helps control glucose, reduces need for insulin in patients with type 1 diabetes

Study: New oral drug helps control glucose, reduces need for insulin in patients with type 1 diabetes


Study: New oral drug helps control glucose, reduces need for insulin in patients with type 1 diabetes
A University of Colorado Anschutz Medical Campus study finds sotagliflozin helps control glucose and reduces the need for insulin in patients with type 1 diabetes .
Principal results were published today in the New England Journal of Medicine of a global Phase 3 clinical trial in patients with type 1 diabetes treated with sotagliflozin. Sotagliflozin is an investigational new oral drug for patients with type 1 diabetes that has shown promise in improving glucose control without any increase in severe hypoglycemia or diabetic ketoacidosis compared to insulin alone.
Among 1,402 trial participants given the drug, sotagliflozin showed clinically meaningful and statistically significant effects on glucose control. Concentrations of hemoglobin A1C, a measure of plasma glucose, were improved. Patients experienced a lower rate of confirmed severe hypoglycemia than observed in patients on placebo and also had weight loss.
According to lead investigator Satish Garg, MD, professor of medicine and pediatrics at the Barbara Davis Center for Diabetes at the University of Colorado Anschutz Medical Campus, no oral medication has ever been approved for the treatment of type 1 diabetes and sotagliflozin has the potential to become the first new treatment innovation in nearly a century since insulin.
Most patients do not achieve optimal glycemic control with insulin alone. A1C concentrations, hypertension and reduction in body weight are critical issues which significantly impact peopl Continue reading

Preventing Prediabetes from Becoming Diabetes by 80%

Preventing Prediabetes from Becoming Diabetes by 80%


Home / Conditions / Obesity / Preventing Prediabetes from Becoming Diabetes by 80%
Preventing Prediabetes from Becoming Diabetes by 80%
In a new international clinical trial, it was shown that the drug liraglutide 3.0 mg may reduce diabetes risk by 80% in individuals with obesity and prediabetes.
Prediabetes, also commonly referred to as borderline diabetes, is a metabolic condition and growing global problem that is closely tied to obesity. If undiagnosed or untreated, prediabetes can develop into type 2 diabetes; which, whilst treatable, is currently not fully reversible.
At this point in time (March 1, 2017), the FDA has not approved any drugs to treat prediabetes, except to improve nutrition and increase physical activity, even though a number of drugs have been shown in studies to reduce the risk of prediabetes becoming diabetes.
The study ran between June 1, 2011, and March 2, 2015. They randomly assigned 2,254 patients to receive liraglutide (n=1505) or placebo (n=749). 1,128 (50%) participants completed the study up to week 160, after withdrawal of 714 (47%) participants in the liraglutide group and 412 (55%) participants in the placebo group. By week 160, 26 (2%) of the 1,472 individuals in the liraglutide group versus 46 (6%) of 738 in the placebo group were diagnosed with diabetes while on treatment. The mean time from randomization to diagnosis was 99 (SD 47) weeks for the 26 individuals in the liraglutide group versus 87 (47) weeks for the 46 individuals in the placebo group. Taking the different diagnosis frequencies between the treatment groups into ac Continue reading

Clemson receives $2.66M for diabetes prevention, nurse practitioner diversity efforts

Clemson receives $2.66M for diabetes prevention, nurse practitioner diversity efforts

GREENVILLE — The Greenville Health Authority board (GHA) has awarded Clemson University a total of $2.66 million for diabetes prevention efforts and scholarships to increase diversity in the nurse practitioner workforce.
Clemson University’s public health sciences department and Clemson Cooperative Extension received a grant for $2.25 million to fund a diabetes prevention and management initiative, while Clemson’s School of Nursing received a grant for $410,000 to provide scholarships for nurse practitioner students.
The Greenville Health Authority board, previously known as the Greenville Health System (GHS) board of trustees, is providing the funding as part of a 20-year pledge to make Greenville County the healthiest in America by 2036. All grant recipients will be honored at a reception at 3 p.m. Thursday in the Greenville Memorial Hospital Community Room located at 701 Grove Road in Greenville.
Diabetes prevention and control
The Integrated Services for Diabetes Prevention and Management initiative is co-led by Clemson’s department of public health sciences, Clemson Cooperative Extension and GHS.
This five-year initiative connects Clemson with diabetes prevention and management efforts at Greenville Health System as well as initiatives of the South Carolina Department of Health and Environmental Control, the South Carolina Lieutenant Governor’s Office on Aging and the American Diabetes Association.
A key component of the initiative is research collaboration between Clemson public health sciences and Cooperative Extension. The program provides a unique opportu Continue reading

No more pages to load

Popular Articles

Related Articles